Amgen bets on stem cell company Fortuna Fix in $25M round
Amgen’s venture arm just made a bet on regenerative medicine for the first time. The pharma giant pitched in to a new $25 million financing round for Canadian stem cell company Fortuna Fix.
Fortuna is working on new ways to regrow neural tissue damaged by degeneration and trauma. With its technology, the company hopes to mimic the capabilities of the Mexican salamander, known for its ability to regrow its own spinal cord, jaw, tail, skin and limbs — all without scarring.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.